Founding Cohort 2026, 9 spots remaining · 50% off Founders Rate For Life →
Authoritize.ai

Industries

Marketing peptide therapy without crossing the FDA

Most therapeutic peptides are not FDA-approved, and several now sit on the agency’s do-not-compound lists. That makes peptide marketing the sharpest enforcement edge in the field. Authoritize builds owned, physician-signed content that educates patients without the claims that draw letters.

Why peptides are the sharpest enforcement edge

Many of the peptides clinics market, including ones like BPC-157, are not FDA-approved drugs, and the FDA placed several into the bulk-substances category that effectively restricts compounding them. Marketing an unapproved drug for a therapeutic benefit, or leaning on a research-use-only label while quietly selling to patients, is exactly the pattern regulators act on. Our peptide enforcement guide breaks down the concrete cases, and the Atlas catalogs the real actions.

Educate without prescribing claims

The line here is sharper than in other verticals, so the content has to be more disciplined. Describe the science and the approval status accurately, avoid disease-treatment and performance claims for anything the FDA has not cleared, be transparent about what is and is not approved, and keep a licensed physician accountable for every clinical statement. A page built that way still answers the questions patients are searching, and it does not turn into a liability the moment a regulator reads it.

What Authoritize builds for peptide clinics

Owned articles and authority pages that answer real patient questions about what peptides are, how they are regulated, and what your practice does, screened against FDA and FTC guidelines inside the pipeline, and signed by your supervising physician as the reviewer of record. It is the same content engine described on our compliant content page, tuned to the tightest vertical we serve. You can pressure-test any existing page right now in the free Claim Checker.

Frequently asked questions

How do you market peptide therapy without an FDA warning letter?

Peptides are the highest-exposure corner of clinic marketing, because most therapeutic peptides are not FDA-approved and several now sit on the agency’s do-not-compound lists. The safe path is education without therapeutic claims: explain what a peptide is and its actual regulatory status, and never promise a benefit for a compound the FDA has not cleared. Authoritize builds owned, physician-signed content that does exactly that, screened against real enforcement patterns. The free Claim Checker runs the screen on copy you already have.

Why are peptides such an enforcement risk right now?

Many of the peptides clinics market, including ones like BPC-157, are not FDA-approved drugs, and the FDA moved several into the bulk-substances category that effectively restricts compounding them. Marketing an unapproved drug for a therapeutic benefit, or leaning on a research-use-only label while selling to patients, is precisely the pattern that draws letters. The regulatory status is the story, and the copy has to respect it.

Can a peptide clinic do any compliant marketing?

Yes, but the line is sharper than in other verticals. Describe the science and the approval status accurately, avoid disease-treatment and performance claims for compounds that are not approved, be transparent rather than coy about what is and is not cleared, and keep a licensed physician accountable for every clinical statement. The honest version of the page is also the defensible one.

Does Authoritize replace our physician’s review?

No. Authoritize screens content against documented enforcement patterns and drafts it to be defensible, but your supervising physician is the reviewer of record and the final gate on every clinical claim. The screen informs that review, it never substitutes for it.